Research Consensus
Building a shared and verifiable language around aging diagnostics, biological age assessment, epigenetic clocks, and multi-omics biomarkers.
About Longevity 121
A long-term meeting platform for healthy longevity
Longevity 121 connects academic research, clinical practice, industry innovation, and capital ecosystems to help move healthy longevity technologies from scientific discovery to application.
Position
Global forum series
Theme
AI-Driven Healthy Longevity
Bridge
Academia, clinical practice, industry, and capital
Forum Introduction
The forum focuses on pathways for extending healthspan and translating AI and frontier life sciences into real-world applications.
Longevity 121 AI & Healthy Longevity Technology Forum 2026 is a key edition of the Longevity 121 global forum series.
Under the theme “AI-Driven Healthy Longevity,” the forum will feature in-depth discussions on aging diagnostics and biomarkers, AI-powered drug discovery, precision interventions, regenerative medicine, clinical translation, and the commercialization of longevity technologies.
The forum will bring together leading scientists, clinical experts, industry pioneers, investors, and innovation-driven companies from around the world to discuss key pathways for advancing healthy longevity from fundamental research to real-world applications.
Conference Background
Population aging, AI technology, and the Boston life science ecosystem form the context for this edition.
Global population aging is accelerating, making the extension of healthspan a critical challenge for the life sciences, healthcare, and broader socioeconomic systems.
At the same time, artificial intelligence is reshaping the technological paradigm for aging research and health interventions. From multi-omics data analysis and biological age assessment to target discovery, drug development, personalized interventions, and clinical translation, AI is opening new pathways for the longevity industry.
As a global hub for life sciences, medical research, and technological innovation, Boston brings together Harvard, MIT, leading hospitals, pharmaceutical companies, biotech startups, and the venture capital ecosystem. Longevity 121 aims to connect academia, clinical practice, industry, and capital within this innovation ecosystem, fostering cross-disciplinary collaboration in healthy longevity.
Forum Focus
Longevity 121 is structured around research consensus, clinical pathways, technology translation, and long-term collaboration.
Clinical Translation
Focusing on how laboratory findings move into clinical validation, health management, and intervention pathways for age-related diseases.
Industry Collaboration
Connecting pharmaceutical companies, biotech firms, healthcare institutions, AI companies, investors, and innovation-driven companies through a long-term network.
Partnership and sponsorship
For sponsorship, partnership, speaking opportunities, or closed-door session inquiries, please contact the conference team.
Chenxi Li
Gavin Zhou